PTEN and breast carcinoma: Retrospective analyses of breast cancer patients receiving combination therapy with trastuzumab and taxane revealed associations between PTEN aberration and diminished responsiveness to trastuzumab, supported by studies in cell cultures and animal models demonstrating the impact of PTEN on reducing the antitumor effects of trastuzumab.24